×

Cookie Settings

We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operations of the website, as well as cookies that are only used for anonymous statistical purposes, for comfort settings or to display personalized content. Please note that based on your settings, it is possible that not all functionalities of the website will be available. You can find further information in our privacy policy.

Please make your personal preference here:

Imprint

 
 
Shopping Cart - CHF 0.00

You have no items in your shopping cart.

  • Home  » 
  • 4013696
Return to Previous Page
4013696

Availability: In stock

α-CGRP (8-37) (human) trifluoroacetate salt
H-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH₂ trifluoroacetate salt

4013696

Product No. Pack Size Available ADS InfoAnalytical Data Sheet List Price Online Order Price Qty
4013696.0001 1 mg Ships within 1 business day ADSExemplary Data Sheet of a current available lot.
CHF 315.00
CHF 292.95 (7%)
4013696.0005 5 mg Ships within 1 business day ADSExemplary Data Sheet of a current available lot.
CHF 1,261.00
CHF 1,172.73 (7%)

Details

CGRP and calcitonin cross-react with each other at the levels of their distinct receptors. α-CGRP (8-37) has been described as a selective antagonist for CGRP receptors but not for calcitonin receptors. This fragment thus appears to be a valuable tool for receptor characterization studies.
Catalog Number H-9895
APC Number 22-5-17
One Letter Code VTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH₂
Synonyms CGRP-I (8-37) (human), Calcitonin Gene-Related Peptide I (8-37) (human)
Molecular Formula C₁₃₉H₂₃₀N₄₄O₃₈
Relative Molecular Mass 3125.63
CAS Registry Number 119911-68-1
Source Synthetic
Storage Conditions -20 ± 5 °C
Keywords CGRP antagonist
Links / Documents:
Brochures:

Bachem product citations

J.V.Bodkin et al., Pharmacol. Res. Perspect, 2, e00052 (2014)
L.L.Nikitenko et al., J. Invest. Dermatol., 133, 1768 (2013)
M.Aslam et al., Br. J. Pharmacol., 165, 208 (2012)
J.Huang et al., Brain Behav. Immun., 25, 787 (2011)
L.Liu et al., Jop., 12, 389 (2011)
M.De Felice et al., Ann. Neurol., 67, 325 (2010)
M.J.Meens et al., PLoS One, 5, e10917 (2010)
A.P.Fontes-Sousa et al., Peptides, 30, 796 (2009)
M.Morfis et al., Endocrinology, 149, 5423 (2008)
N.J.Spencer et al., Neuroscience, 153, 518 (2008)
A.Thievent et al., Peptides, 26, 1567 (2005)
C.Nodin et al., Biochem. Pharmacol., 69, 1235 (2005)
D.L.Hay et al., Mol. Pharmacol., 67, 1655 (2005)
P.Hasbak et al., Br. J. Pharmacol., 145, 646 (2005)
C.Schaeffer et al., Biochim. Biophys. Acta, 1643, 65 (2003)
E.S.Dettmann et al., Invest. Ophthalmol. Vis. Sci., 44, 3961 (2003)
J.J.Miret et al., J. Biol. Chem., 277, 6881 (2002)
M.D.Harzenetter et al., Exp. Hematol., 30, 306 (2002)
M.Zaki et al., Gastroenterology, 123, 247 (2002)
J.Liu et al., Immunology, 101, 61 (2000)
K.Leuthauser et al., Biochem. J., 351, 347 (2000)
H.J.Habler et al., Neuroscience, 89, 1259 (1999)
N.Aiyar et al., Mol. Cell. Biochem., 197, 179 (1999)

Product citations

G.Gherardini et al., Neuropeptides, 32, 269 (1998)
U.Zimmermann et al., Peptides, 16, 421 (1995)
T.Chiba et al., Am. J. Physiol., 256, E331 (1989)